Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Formycon stock

FYB.DE
DE000A1EWVY8
A1EWVY

Price

54.70
Today +/-
+1.20
Today %
+2.22 %

Formycon stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Formycon stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Formycon stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Formycon stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Formycon's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Formycon Stock Price History

DateFormycon Price
2/6/202554.70 undefined
2/5/202553.50 undefined
2/4/202552.00 undefined
2/3/202552.80 undefined
1/31/202553.60 undefined
1/30/202554.10 undefined
1/29/202554.50 undefined
1/28/202554.80 undefined
1/27/202552.80 undefined
1/24/202554.90 undefined
1/23/202554.60 undefined
1/22/202555.10 undefined
1/21/202554.30 undefined
1/20/202556.40 undefined
1/17/202556.00 undefined
1/16/202557.30 undefined
1/15/202558.00 undefined
1/14/202558.70 undefined
1/13/202559.80 undefined
1/10/202562.70 undefined
1/9/202561.80 undefined

Formycon Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Formycon, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Formycon from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Formycon’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Formycon. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Formycon’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Formycon’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Formycon’s growth potential.

Formycon Revenue, EBIT and net profit per share

DateFormycon RevenueFormycon EBITFormycon Net Income
2030e227.01 M undefined0 undefined0 undefined
2029e214.09 M undefined54.31 M undefined0 undefined
2028e230.62 M undefined101.69 M undefined0 undefined
2027e224.96 M undefined124.1 M undefined86.63 M undefined
2026e183.36 M undefined85.01 M undefined70.66 M undefined
2025e90.97 M undefined-8.41 M undefined4.03 M undefined
2024e61.47 M undefined-6.84 M undefined-9.63 M undefined
202377.7 M undefined-369,000 undefined75.8 M undefined
202242.5 M undefined-17.73 M undefined35.99 M undefined
202136.61 M undefined-14 M undefined-13.29 M undefined
202034.3 M undefined-6.54 M undefined-6.73 M undefined
201933.92 M undefined-2.21 M undefined-2.29 M undefined
201843.18 M undefined7.19 M undefined7.1 M undefined
201729.11 M undefined-1.51 M undefined-1.58 M undefined
201619.66 M undefined-3.97 M undefined-4.07 M undefined
201517.15 M undefined696,450 undefined577,520 undefined
201412.67 M undefined873,280 undefined860,330 undefined
2013410,000 undefined-7.74 M undefined-7.74 M undefined
2012550,000 undefined-2.46 M undefined-2.4 M undefined
2011100,000 undefined-1.36 M undefined-1.29 M undefined
201050,000 undefined-1.02 M undefined-1.01 M undefined

Formycon Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000121719294333343642776190183224230214227
-----41.6711.7652.6348.28-23.263.035.8816.6783.33-20.7847.54103.3322.402.68-6.966.07
----50.0047.0621.0527.5941.8633.3320.5925.0028.5728.5736.0724.4412.029.829.5710.289.69
000-1684818117912220000000
-1-1-2-700-4-17-2-6-133575-947086000
--100.00250.00----75.00-800.00-128.57200.00116.67-369.23114.29-112.00-144.441,650.0022.86---
7.247.247.418.68.639.089.19.349.4210111113.8816.050000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Formycon Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Formycon is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20102011201220132014201520162017201820192020202120222023
                           
3.871.80.2210.49.2220.313.6115.4812.3122.3542.2525.189.8227.04
000.0203.252.764.1110.525.174.927.7111.9415.4828.17
0250100000000000131
0.040.050.080.270.350.230.610.581.220.410.090.210.570.47
0.110.060.120.230.050.120.970.140.20.50.381.239.2722.67
4.022.160.4510.912.8823.4119.3126.7118.8928.1850.4338.5635.1478.48
0.150.33.752.992.692.613.413.263.473.79.258.4311.5212.33
0.070.100000.05015.9720.6720.6323.62278.71257.95
0300001.560000000
0.050.040.260.180.120.070.080.110.180.20.270.73488.44508.4
001.541.381.221.060.910.750.590.430044.5344.53
00000000519.73700000
0.273.445.554.554.033.746.014.1120.7325.3830.1532.77823.2823.22
4.295.6615.4516.9127.1525.3130.8339.6253.5680.5871.33858.33901.7
                           
4.244.585.088.638.639.089.19.349.42101111.0715.1316.05
00000000000000
-0.170.56-2.533.624.4815.7913.3916.223.8238.2155.944.83341.45486.7
000000000080.5682.78343.420
00000000000000
4.075.142.5512.2513.1124.8722.4925.5433.2448.21147.46138.67700502.75
0.0503.112.492.490.6501.772.732.215.267.6111.3216.32
0.020.010000.010.010001.171.191.292.68
0.140.160.090.50.530.660.712.612.871.910.370.7416.3428.63
00000000000000
00.29000000000.980.8821.7221.67
0.210.463.22.993.021.320.714.385.64.127.7810.4250.6769.31
00000000004.984.4127.597.87
000000000.520.520.920119.52122.8
000.250.210.990.962.110.90.260.700299.34187.64
000.250.210.990.962.110.90.781.225.94.41446.45318.3
0.210.463.453.24.022.282.835.286.385.3413.6814.82497.12387.61
00.010.010.020.020.030.030.030.040.050.160.151.20.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Formycon provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Formycon's financial health and stability.

Assets

Formycon's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Formycon must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Formycon after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Formycon's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2010201120122013201420152016201720182019202020212022
-1-1-2-700-4-17-2-6-1335
0001,0001,000000001,0001,0001,000
0000000000000
003-10-1-1-1-3400-1-3
-2,00001,00000000001,0000-52,000
0000000000000
0000000000000
-203-1600-5-413-1-4-13-18
00-5000-10-1-100-26
0-3-4000-10-17-50-3-37
0-3,0001,00000000-15,000-4,0000-2,000-10,000
0000000000000
00000000000-139
000171711060172511
421170110601724040
4210000000000
0000000000000
1-100011-61-31019-16-15
-3.08-0.99-2.38-16.77-0.6-0.15-6.43-4.6812.23-2.49-4.8-14.3-45.64
0000000000000

Formycon stock margins

The Formycon margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Formycon. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Formycon.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Formycon's sales revenue. A higher gross margin percentage indicates that the Formycon retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Formycon's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Formycon's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Formycon's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Formycon. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Formycon's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Formycon Margin History

Formycon Gross marginFormycon Profit marginFormycon EBIT marginFormycon Profit margin
2030e29.49 %0 %0 %
2029e29.49 %25.37 %0 %
2028e29.49 %44.09 %0 %
2027e29.49 %55.17 %38.51 %
2026e29.49 %46.36 %38.54 %
2025e29.49 %-9.25 %4.43 %
2024e29.49 %-11.13 %-15.67 %
202329.49 %-0.47 %97.55 %
202228.41 %-41.72 %84.69 %
202126.96 %-38.24 %-36.3 %
202022.25 %-19.07 %-19.62 %
201934.59 %-6.52 %-6.76 %
201843.79 %16.65 %16.44 %
201728.73 %-5.2 %-5.43 %
201621.75 %-20.21 %-20.68 %
201548.23 %4.06 %3.37 %
201453.37 %6.89 %6.79 %
2013-263.41 %-1,887.8 %-1,887.8 %
201285.45 %-447.27 %-436.36 %
201170 %-1,360 %-1,290 %
201080 %-2,040 %-2,020 %

Formycon Stock Sales Revenue, EBIT, Earnings per Share

The Formycon earnings per share therefore indicates how much revenue Formycon has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Formycon earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Formycon's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Formycon’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Formycon's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Formycon Revenue, EBIT and net profit per share

DateFormycon Sales per ShareFormycon EBIT per shareFormycon Earnings per Share
2030e12.85 undefined0 undefined0 undefined
2029e12.12 undefined0 undefined0 undefined
2028e13.06 undefined0 undefined0 undefined
2027e12.74 undefined0 undefined4.91 undefined
2026e10.38 undefined0 undefined4 undefined
2025e5.15 undefined0 undefined0.23 undefined
2024e3.48 undefined0 undefined-0.55 undefined
20234.84 undefined-0.02 undefined4.72 undefined
20223.06 undefined-1.28 undefined2.59 undefined
20213.33 undefined-1.27 undefined-1.21 undefined
20203.12 undefined-0.59 undefined-0.61 undefined
20193.39 undefined-0.22 undefined-0.23 undefined
20184.58 undefined0.76 undefined0.75 undefined
20173.12 undefined-0.16 undefined-0.17 undefined
20162.16 undefined-0.44 undefined-0.45 undefined
20151.89 undefined0.08 undefined0.06 undefined
20141.47 undefined0.1 undefined0.1 undefined
20130.05 undefined-0.9 undefined-0.9 undefined
20120.07 undefined-0.33 undefined-0.32 undefined
20110.01 undefined-0.19 undefined-0.18 undefined
20100.01 undefined-0.14 undefined-0.14 undefined

Formycon business model

Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.com.

Formycon SWOT Analysis

Strengths

Formycon AG has a strong portfolio of biosimilar products, positioning itself as a key player in the pharmaceutical industry.

The company's partnerships with major pharmaceutical companies provide it with access to resources, expertise, and distribution channels.

Formycon AG has a robust research and development pipeline, constantly working on innovative solutions and enhancing its product offerings.

Weaknesses

The company heavily relies on its partnerships, making it susceptible to changes in business relationships and potential dependency.

Formycon AG may face challenges in obtaining regulatory approvals for its biosimilar products, which can lead to delays and increased costs.

The company's limited marketing and promotional activities may hinder its ability to fully exploit market opportunities.

Opportunities

The increasing demand for affordable healthcare and cost-effective treatment options creates significant opportunities for Formycon AG's biosimilars.

Expansion into new markets and regions presents the company with the chance to diversify its revenue streams and strengthen its global presence.

Strategic collaborations with emerging biotechnology companies can facilitate knowledge exchange and open doors to new research and development opportunities.

Threats

Intense competition from rival companies operating in the biosimilars market poses a threat to Formycon AG's market share and potential profitability.

Changes in healthcare regulations and pricing policies can impact the reimbursement rates and financial viability of the company's products.

Emerging technologies or alternative treatment options could disrupt the demand for Formycon AG's biosimilars.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Formycon Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Formycon historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Formycon shares outstanding

The number of shares was Formycon in 2024 — This indicates how many shares 16.049 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Formycon earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Formycon's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Formycon’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Formycon's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Formycon.

Formycon shareholders

%
Name
Stocks
Change
Date
24.29574 % Athos KG4,290,627010/17/2024
13.59762 % Family Office Wendeln2,401,339010/17/2024
8.99842 % Gedeon Richter Plc1,589,121-14,75610/17/2024
5.99895 % Active Ownership Capital S.¿.r.l.1,059,414010/17/2024
4.99912 % DSP Beteiligungsgesellschaft GmbH & Co. KG882,845010/17/2024
2.20048 % Stiller (Olaf)388,605010/17/2024
1.98188 % Combe (Nicoals)350,000010/17/2024
1.74062 % Brockmeyer (Carsten)307,394010/17/2024
0.90922 % Norges Bank Investment Management (NBIM)160,5689,4246/30/2024
0.86908 % ACATIS Investment Kapitalverwaltungsgesellschaft GmbH153,47908/31/2024
1
2
3
4
5
...
7

Formycon Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Teva Pharmaceutical Inds Stock
Teva Pharmaceutical Inds
SupplierCustomer0,880,480,530,430,230,06
1

Most common questions regarding Formycon

What values and corporate philosophy does Formycon represent?

Formycon AG represents values of innovation, excellence, and sustainability in the pharmaceutical industry. Committed to advancing biosimilar drug development, Formycon AG focuses on enhancing patient access to affordable treatments. The company strives to create high-quality and safe biosimilars, providing patients with effective alternatives to expensive originator drugs. Formycon AG's corporate philosophy is rooted in their dedication to delivering high-value propositions that benefit both patients and healthcare systems. By leveraging their expertise in molecular biology and biotechnology, Formycon AG aims to address the unmet medical needs and improve the quality of life for patients worldwide.

In which countries and regions is Formycon primarily present?

Formycon AG is primarily present in Germany, where it is headquartered. As a leading biopharmaceutical company, Formycon operates in various regions across the globe. However, its primary focus remains on the German market, leveraging its expertise in biosimilar drugs. With a strong presence in Germany, Formycon AG aims to contribute to the development and accessibility of high-quality and affordable medicines for patients.

What significant milestones has the company Formycon achieved?

Formycon AG, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company has successfully developed and commercialized cost-effective biosimilar medicines for various diseases. Formycon AG has gained regulatory approvals for several products, including biosimilar candidates for eye diseases, such as ranibizumab and aflibercept. Moreover, the company has entered into strategic partnerships with prominent pharmaceutical companies, expanding its global reach and market presence. Formycon AG's commitment to innovation and extensive research has driven its success in delivering high-quality and affordable treatments. With its steadfast dedication, Formycon AG continues to redefine healthcare standards and improve patient access to life-saving medications.

What is the history and background of the company Formycon?

Formycon AG is a renowned biopharmaceutical company based in Germany. Established in 2010, the company specializes in the development and production of biosimilars, which are biological drugs highly similar to existing approved products. As a significant player in the industry, Formycon AG aims to make healthcare more affordable and accessible by providing cost-effective biosimilar solutions. The company's expertise lies in the fields of rheumatology, ophthalmology, and oncology, among others. With a strong commitment to research and innovation, Formycon AG has successfully built a robust pipeline of biosimilar candidates and established partnerships with major pharmaceutical companies.

Who are the main competitors of Formycon in the market?

The main competitors of Formycon AG in the market include major pharmaceutical companies such as Novartis, Pfizer, Roche, and Sanofi.

In which industries is Formycon primarily active?

Formycon AG is primarily active in the pharmaceutical industry.

What is the business model of Formycon?

The business model of Formycon AG is focused on the development and commercialization of high-quality biosimilar medicines. As a biopharmaceutical company, Formycon specializes in the production of affordable and safe alternatives to expensive biological drugs. By leveraging its proprietary technology and extensive expertise, Formycon aims to address unmet medical needs and improve patient access to therapies. The company collaborates with strategic partners to carry out the research, development, and clinical trials required for regulatory approval. Through its commitment to innovation and cost-effectiveness, Formycon AG strives to contribute to the betterment of healthcare systems worldwide.

What is the P/E ratio of Formycon 2025?

The Formycon P/E ratio is 218.05.

What is the P/S ratio of Formycon 2025?

The Formycon P/S ratio is 9.65.

What is the Quality Investing of Formycon?

The Quality Investing for Formycon is 4/10.

What is the revenue of Formycon 2025?

The expected Formycon revenue is 90.97 M EUR.

How high is the profit of Formycon 2025?

The expected Formycon profit is 4.03 M EUR.

What is the business model of Formycon

The Formycon AG is a biotechnology company specializing in biosimilars. Their business model is to offer more affordable versions of biotechnologically manufactured medicines already on the market. Biosimilars are biologically produced medicines that have similar active ingredients to already approved original preparations and have the same therapeutic effect. The company specializes in developing biosimilars for various therapy areas such as oncology, rheumatology, ophthalmology, and neurology. They focus particularly on established brand products with high value potential. The company conducts research and development in collaboration with partners and clients from the pharmaceutical industry and utilizes its biotechnology expertise in areas such as cell line development, fermentation processes, and the purification of active ingredients. In addition to development, the company aims to successfully market its biosimilars by partnering with established pharmaceutical companies for global distribution channels and rapid entry into key markets. The Formycon AG is currently working on several biosimilars in different stages of clinical development. They also offer consulting services related to biosimilars, leveraging their extensive biotechnology knowledge to support customers in bringing biosimilars to market. In summary, Formycon AG offers a comprehensive range of services including biosimilar development, marketing and distribution support, and biotechnology consulting. Through their focus on biosimilars and partnerships with established pharmaceutical companies, they can quickly and successfully enter the market and establish themselves as a leading provider.

What is the Formycon dividend?

Formycon pays a dividend of 0 EUR distributed over payouts per year.

How often does Formycon pay dividends?

The dividend cannot currently be calculated for Formycon or the company does not pay out a dividend.

What is the Formycon ISIN?

The ISIN of Formycon is DE000A1EWVY8.

What is the Formycon WKN?

The WKN of Formycon is A1EWVY.

What is the Formycon ticker?

The ticker of Formycon is FYB.DE.

How much dividend does Formycon pay?

Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.

What is the dividend yield of Formycon?

The current dividend yield of Formycon is .

When does Formycon pay dividends?

Formycon pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Formycon?

Formycon paid dividends every year for the past 0 years.

What is the dividend of Formycon?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Formycon located?

Formycon is assigned to the 'Health' sector.

Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Formycon from 2/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 2/7/2025.

When did Formycon pay the last dividend?

The last dividend was paid out on 2/7/2025.

What was the dividend of Formycon in the year 2024?

In the year 2024, Formycon distributed 0 EUR as dividends.

In which currency does Formycon pay out the dividend?

The dividends of Formycon are distributed in EUR.

All fundamentals about Formycon

Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.